February 28, 2026 · Phase 3 readout
NVS Phase 3 readout: a positive outcome, -1.0%
-1.0%Novartis AG (NVS) →
On February 28, 2026, JDQ443 — Novartis AG (Non-Small Cell Lung Cancer) reached its Phase 3 readout. The result was a positive outcome, and the stock moved -1.0% in the window around the event. It had already run +15.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$168.62
1d before
$168.62
Event day
$166.87
1d after
$166.87
5d after
Pre-catalyst setup
+15.6%
30-day run-up
1914%
30-day volatility
1.7×
volume spike